Nexalin Technology, Inc. (NASDAQ: NXL) reported a loss of $0.13 per share for its fourth quarter of 2025, missing the consensus estimate of a $0.12 loss by 8.33%. The company generated $171.895 k in revenue for the quarter, surpassing the $80 k consensus estimate and representing a dramatic increase from the $18.15 k reported in Q3 2025.
The earnings miss reflects continued cash burn and challenges in achieving profitability. Management highlighted that the company remains under significant financial strain, citing a substantial going‑concern warning in its most recent audit report and a Nasdaq bid‑price compliance deadline of July 20 2026. The company’s guidance for the next quarter, scheduled for June 3 2026, projects an EPS of –$0.12 and revenue of $80.8 k, indicating a cautious outlook amid ongoing capital‑raising needs.
Revenue growth was driven largely by increased device and equipment sales to international customers, offset by a decline in licensing fees. The company’s gross margin remained strong at approximately 80%, but operating expenses continued to outpace revenue growth, contributing to the net loss. The guidance signals management’s confidence in maintaining high gross margins while acknowledging the need for cost containment and additional capital to support its strategic pivot to Gen‑2 and Gen‑3 neurostimulation systems.
The company’s strategic focus on new device approvals, particularly in the U.S. market, remains a key tailwind, but the lack of FDA clearance for its new devices and the inability to market its legacy device in the U.S. present significant headwinds. The company’s international approvals in China, Oman, and Brazil provide growth opportunities, yet the overall financial health remains precarious due to the auditor’s substantial doubt about continued operations.
Investors will monitor Nexalin’s ability to secure additional funding and achieve regulatory milestones, as these factors will determine the company’s ability to sustain its current operating model and pursue its long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.